Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma

Wu, Xuechao; Wang, Yingyi; Yu, Tianfu; Nie, Er; Hu, Qi; Wu, Weining; Zhi, Tongle; Jiang, Kuan; Wang, Xiefeng; Lu, Xiaojie; Li, Hailin; Liu, Ning; Zhang, Junxia; You, Yongping

doi:10.1093/neuonc/nox017

Cited by 116 publications

(112 citation statements)

References 38 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 80%

“…In this report, we analyzed the expression of MIR155HG in various cancers and paracancer or normal tissues, and analyzed the relationship between MIR155HG expression and OS, DFS and staging, consistent with Wu's finding that MIR155HG was associated with poor tumor prognosis in glioma. 10 As reported, the expression of MIR155HG was significantly higher in cancer than paracancer in KIRC, 26 and MIR155HG was associated with poor OS. 27 GO and KEGG analysis in these types of tumors showed that mRNAs co-expressed with MIR155HG were mostly enriched in immune-related functions and immune-related pathways, which indicated that MIR155HG may be related to immunity.…”

Section: Discussionmentioning

confidence: 67%

“…It also has oncogene activity in transgenic mouse models . MIR155 host gene promotes glioma and GBM tumor growth, and is associated with colorectal cancer pancreatic cancer, laryngeal squamous cell carcinoma . Multiple studies have shown that MIR155HG is highly expressed in diffuse large B‐cell (DLBC) lymphoma and primary mediastinal B‐cell lymphoma .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

et al. 2019

View full text Add to dashboard Cite

In recent years, immune checkpoint inhibitor has achieved remarkable success in multiple cancer treatment. However, how to pre‐judge which patients are suitable for immune checkpoint inhibitor is a difficult problem. We use the existing public bioinformatics database to comprehensively analyze the relationship between clinical data of various cancers with immune checkpoint blocking molecules and long non‐coding RNAs (lncRNAs), and try to find the potential predictive value of lncRNA for immunotherapy with checkpoint inhibitors. In this study, we found that: (a) high expression of lncRNA MIR155 host gene (MIR155HG) was closely related to better overall survival (OS) in cholangiocarcinoma (CHOL), lung adenocarcinoma (LUAD), and skin cutaneous melanoma (SKCM), and have better disease‐free survival (DFS) in CHOL. Meanwhile, the high level of MIR155HG was associated with poorer OS in glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), brain lower grade glioma (LGG), and uveal melanoma (UVM). (b) The expression of MIR155HG was significantly correlated with infiltrating levels of immune cells and immune molecules, especially with immune checkpoint molecules such as programmed cell death protein 1 (PD‐1), PD‐1 ligand 1 (PD‐L1), and cytotoxic T lymphocyte‐associated antigen 4 (CTLA4) in most kinds of cancers. (c) Detection of clinical CHOL and liver hepatocellular carcinoma tissues confirmed that there was a strong positive correlation between MIR155HG expression and the levels of CTLA4 and PD‐L1. MIR155 host gene can be used as a prognostic marker in multiple cancers, and of great value in predicting the curative effect of immune checkpoint inhibitor therapy owing to it is closely related with immune cells infiltration and immune checkpoint molecules expression.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that lncRNA MIR155HG plays key roles in the development of myeloproliferative disorders, leukemia, lymphoma, and glioma [40][41][42]. lncRNA MIR155HG can suppress lymphoma by regulating the activity of NF-κB and mesenchymal genes [42].…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma

Song

Peng²,

Zhu³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Kidney renal clear cell carcinoma (KIRC) is one of the most fatal malignancies due to late diagnosis and poor treatment. To improve its prognosis, a screening for molecular biomarkers of KIRC is urgently needed. Long non-coding RNAs (lncRNAs) play important roles in tumorigenesis and prognosis of cancers. However, it is not clear whether lncRNAs can be used as molecular biomarkers in predicting the survival of KIRC patients. Methods: In this study, our aim was to identify lncRNAs/mRNAs signatures and their prognostic values in KIRC. The aberrant expression profile of mRNAs and lncRNAs in 529 KIRC tissues and 72 adjacent non-tumor pancreatic tissues were obtained from the Cancer Genome Atlas (TCGA). A weighted gene co-expression network analysis (WGCNA) of two key lncRNAs was constructed. We constructed an aberrant lncRNA-mRNA-miRNA ceRNA network in CESC. In addition, Gene Ontology (GO) and KEGG pathway analysis were performed. Results: Using lncRNA/mRNA expression profiling data, the overall analysis revealed that two novel lncRNA signatures (DNM1P35 and MIR155HG) and several mRNAs were found to be significantly correlated with KIRC patient’s overall analysis. Based on the target gene of the two lncRNA in co-expression network, the GO and KEGG analysis were also performed. A dysregulated lncRNA-related ceRNA network was also observed. Conclusion: These results suggested that the two novel lncRNAs signatures may act as independent prognostic biomarkers for predicting the survival of KIRC patient.

show abstract

“…Another study demonstrated that MIR155HG/miR-155 blockade could inhibit mesenchymal transition in glioma. 12 In this study, we measured MIR155HG expression in PC tumor tissue, adjacent normal tissue, cancer cell lines, and a normal pancreatic cell line. We found that higher MIR155HG expression was positively linked to the poor prognosis of the patients.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA MIR155HG facilitates pancreatic cancer progression through negative regulation of miR‐802

Yan

Liu

Liang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) present the key regulatory functions in tumorigenesis. More and more studies have suggested that lncRNA MIR155HG is involved in different human cancers. However, the underlying regulatory role of lncRNA MIR155HG and potential mechanisms in pancreatic cancer (PC) remain illusive. In this research, our group found that lncRNA MIR155HG expression was remarkably increased in PC tumor tissue and cells compared to that in the adjacent normal tissue and cells. In addition, higher MIR155HG expression was positively associated with the poor prognosis of patients. In addition, we exhibited that silence of MIR155HG by short hairpin RNA knockdown significantly inhibited cell growth and promoted cell apoptosis in PC cells. We performed bioinformatics analysis to search for the target of MIR155HG. As demonstrated by Luciferase reporter assay, we found that miR‐802, a tumor suppressor in various cancer, is a direct target of MIR155HG. We demonstrated that the tumor‐promoting effects of MIR155HG were contributed by negative regulation of miR‐802 in PC cells. In summary, our results suggest that lncRNA MIR155HG might be applied as a novel diagnostic and therapeutic target for PC.

show abstract

Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma

Cited by 116 publications

References 38 publications

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma

Long noncoding RNA MIR155HG facilitates pancreatic cancer progression through negative regulation of miR‐802

Contact Info

Product

Resources

About